Loading…
Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA; Lower Health Care Costs Act (S 1895)
Patient protection; Drug shortages; Drug pricing and value; Lower Health Care Costs Act (S 1895); Transparency; Intellectual Property
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2019 · third_quarter · Q3
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (NHHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
Patient protection; Drug shortages; Drug pricing and value; Lower Health Care Costs Act (S 1895); Transparency; Intellectual Property
Source: Senate LDA
Medicare Decisions Accountability Act of 2011
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicare Part-D non-interference and rebate issues; Medicare Decisions Accountability Act of 2011 (IPAB repeal) (HR 452);
Medicare Decisions Accountability Act of 2011
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicare Part D Non-Interference, Rebate Issues, Medicare Decisions Accountability Act of 2011 - IPAB Repeal (HR 452)
America's Affordable Health Choices Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Healthcare Reform (HR 4872 & HR 3590); FOB provisions (HR 3200)
America's Affordable Health Choices Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicare reimbursement and coverage policies; Healthcare reform (HR 3590 & HR 4872); food safety; Patient Protection and Affordable Care Act (HR 3590); FOB provisions (HR 3200)
Food and Drug Administration Globalization Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
IPAB (S 3590, HR 4872); 340B legislation (S 3590, HR 4872); FDA Foreign Inspections (HR 759); PCORI (S 3590, HR 759); Implementation issues
Carbon Capture and Sequestration Deployment Revenue Act of 2010
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
IPAB (S 3590, HR 4872); 340B legislation (S 3590, HR 4872); FDA Foreign Inspections (HR 759); PCORI (S 3590, HR 759); Implementation issues
American Middle Class Tax (AMT) Relief Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicare reimbursement and coverage policies; Healthcare reform (HR 3590 & HR 4872); food safety; Patient Protection and Affordable Care Act (HR 3590); FOB provisions (HR 3200)
American Middle Class Tax (AMT) Relief Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Healthcare Reform (HR 4872 & HR 3590); FOB provisions (HR 3200)
American Middle Class Tax (AMT) Relief Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Healthcare Reform (HR 4872 & HR 3590)
To suspend temporarily the duty on 1-Amino-2,6-dimethylbenzene.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Healthcare Reform (HR 4872 & HR 3590)
To suspend temporarily the duty on 1-Amino-2,6-dimethylbenzene.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicare reimbursement and coverage policies; Healthcare reform (HR 3590 & HR 4872); food safety; Patient Protection and Affordable Care Act (HR 3590); FOB provisions (HR 3200)
To suspend temporarily the duty on 1-Amino-2,6-dimethylbenzene.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
IPAB (S 3590, HR 4872); 340B legislation (S 3590, HR 4872); FDA Foreign Inspections (HR 759); PCORI (S 3590, HR 759); Implementation issues
To suspend temporarily the duty on 1-Amino-2,6-dimethylbenzene.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Healthcare Reform (HR 4872 & HR 3590); FOB provisions (HR 3200)
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Health Care Reform, Comparative Effectiveness Research (S 1213, HR 2502, S 1259), Drug Importation, Follow-on biologics (HR 1548, HR 1427, S 726)
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
Health Care Reform, Comparative Effectiveness Research (S 1213, HR 2502, S 1259), Drug Importation, Follow-on biologics (HR 1548, HR 1427, S 726)
Comparative Effectiveness Research Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Health Care Reform, Comparative Effectiveness Research (S 1213, HR 2502, S 1259), Drug Importation, Follow-on biologics (HR 1548, HR 1427, S 726)
America's Affordable Health Choices Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
340B Program Improvement and Integrity Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicaid Rebate Increase, Medicaid rebate applied to Medicaid Managed Care Plans, Medicaid rebate applied to Part D, 340B Expansion (HR 444), Transparency
American Recovery and Reinvestment Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
Patient-Centered Outcomes Research Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Health Care Reform, Comparative Effectiveness Research (S 1213, HR 2502, S 1259), Drug Importation, Follow-on biologics (HR 1548, HR 1427, S 726)
Health Care Reform, Comparative Effectiveness Research (S 1213, HR 2502, S 1259), Drug Importation, Follow-on biologics (HR 1548, HR 1427, S 726)
A bill to authorize the award of a Congressional gold medal to the Montford Point Marines of World War II.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
America's Healthy Future Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
Physician Payments Sunshine Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
21st Century Cancer ALERT (Access to Life-Saving Early detection, Research and Treatment) Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
21st Century Cancer Access to Life-Saving Early Detection, Research and Treatment (S 717), Fair Medicaid Drug Payment and Genetic Information Nondiscription Act
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Health Care Reform, Comparative Effectiveness Research (S 1213, HR 2502, S 1259), Drug Importation, Follow-on biologics (HR 1548, HR 1427, S 726)
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
Physician Pathology Services Continuity Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
American Middle Class Tax (AMT) Relief Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Pending draft oncology, Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Comparative Effectiveness (S 3408); Food & Drug Safety (HR 3610); Biosimilars (HR 5629, HR 1956, HR 1038, S 1695); Transparency (S 2029, HR 5605); Healthcare Reform (Belgium, Germany, Italy, United Kingdom, South Africa); MDR-TB
Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Pending draft oncology, Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Pending draft oncology, Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicare (HR 6331), Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038)
Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicare (HR 6331), Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038)
Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicare (HR 6331), Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038)
Stop Tuberculosis (TB) Now Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731, S 968, HR 1567), Follow-on Biologics (S 623 & HR 1956)
Stop Tuberculosis (TB) Now Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilars (S 1695 & HR 5629), healthcare reform, United Kingdom (pricing reform), Italy (healthcare reform & pricing), Germany (healthcare reform & pricing), France (healthcare reform & pricing), funding to fight tuberculosis (HR 5501, S 2731, S 968, HR 1567), Follow-on biologics (S 623 & HR 1956)
Transparency (HR 1669)
Transparency (HR 1669)
Pending draft oncology, Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Pending draft oncology, Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Pending draft oncology, Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Patient Protection and Innovative Biologic Medicines Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Pending draft oncology, Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Patient Protection and Innovative Biologic Medicines Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Patient Protection and Innovative Biologic Medicines Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731, S 968, HR 1567), Follow-on Biologics (S 623 & HR 1956)
Patient Protection and Innovative Biologic Medicines Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Pending draft oncology, Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Patient Protection and Innovative Biologic Medicines Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Comparative Effectiveness (S 3408); Food & Drug Safety (HR 3610); Biosimilars (HR 5629, HR 1956, HR 1038, S 1695); Transparency (S 2029, HR 5605); Healthcare Reform (Belgium, Germany, Italy, United Kingdom, South Africa); MDR-TB
Patient Protection and Innovative Biologic Medicines Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Patient Protection and Innovative Biologic Medicines Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Pending draft oncology, Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Patient Protection and Innovative Biologic Medicines Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicare (HR 6331), Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038)
Patient Protection and Innovative Biologic Medicines Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Patient Protection and Innovative Biologic Medicines Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilars (S 1695 & HR 5629), healthcare reform, United Kingdom (pricing reform), Italy (healthcare reform & pricing), Germany (healthcare reform & pricing), France (healthcare reform & pricing), funding to fight tuberculosis (HR 5501, S 2731, S 968, HR 1567), Follow-on biologics (S 623 & HR 1956)
Patient Protection and Innovative Biologic Medicines Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicare (HR 6331), Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038)
Patient Protection and Innovative Biologic Medicines Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicare (HR 6331), Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038)
Food and Drug Administration Amendments Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Food and Drug Administration Amendments Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Food and Drug Administration Amendments Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Food and Drug Import Safety Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Healthcare Reform in Belgium, Germany, Italy, United Kingdom, South Africa, and MDR-TB, Comparative Effectiveness (S 3408), Food & Drug Safety (HR 3610), Biosimilars (HR 5629), Transparency (S 2029 & HR 5605)
Food and Drug Import Safety Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Comparative Effectiveness (S 3408); Food & Drug Safety (HR 3610); Biosimilars (HR 5629, HR 1956, HR 1038, S 1695); Transparency (S 2029, HR 5605); Healthcare Reform (Belgium, Germany, Italy, United Kingdom, South Africa); MDR-TB
Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilars (S 1695 & HR 5629), healthcare reform, United Kingdom (pricing reform), Italy (healthcare reform & pricing), Germany (healthcare reform & pricing), France (healthcare reform & pricing), funding to fight tuberculosis (HR 5501, S 2731, S 968, HR 1567), Follow-on biologics (S 623 & HR 1956)
Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731, S 968, HR 1567), Follow-on Biologics (S 623 & HR 1956)
Physician Payments Sunshine Act of 2008
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Sunshine Act (S 2029 / HR 5605)
Physician Payments Sunshine Act of 2008
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Healthcare Reform in Belgium, Germany, Italy, United Kingdom, South Africa, and MDR-TB, Comparative Effectiveness (S 3408), Food & Drug Safety (HR 3610), Biosimilars (HR 5629), Transparency (S 2029 & HR 5605)
Physician Payments Sunshine Act of 2008
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Comparative Effectiveness (S 3408); Food & Drug Safety (HR 3610); Biosimilars (HR 5629, HR 1956, HR 1038, S 1695); Transparency (S 2029, HR 5605); Healthcare Reform (Belgium, Germany, Italy, United Kingdom, South Africa); MDR-TB
Physician Payments Sunshine Act of 2008
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Sunshine Act (S 2029, HR 5605)
Physician Payments Sunshine Act of 2008
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Sunshine Act (S 2029, HR 5605)
Physician Payments Sunshine Act of 2008
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Sunshine Act (S 2029, HR 5605)
Physician Payments Sunshine Act of 2008
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Sunshine Act (S 2029, HR 5605)
Healthcare Reform in Belgium, Germany, Italy, United Kingdom, South Africa, and MDR-TB, Comparative Effectiveness (S 3408), Food & Drug Safety (HR 3610), Biosimilars (HR 5629), Transparency (S 2029 & HR 5605)
Comparative Effectiveness (S 3408); Food & Drug Safety (HR 3610); Biosimilars (HR 5629, HR 1956, HR 1038, S 1695); Transparency (S 2029, HR 5605); Healthcare Reform (Belgium, Germany, Italy, United Kingdom, South Africa); MDR-TB
Pending draft oncology, Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Pending draft oncology, Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Medicare (HR 6331), Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038)
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Access for uninsured (S 1886 & S 1975), Biosimilars (S 1695 & HR 5629), healthcare reform, United Kingdom (pricing reform), Italy (healthcare reform & pricing), Germany (healthcare reform & pricing), France (healthcare reform & pricing), funding to fight tuberculosis (HR 5501, S 2731, S 968, HR 1567), Follow-on biologics (S 623 & HR 1956)
Medicare (HR 6331), Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038)
Medicare (HR 6331), Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038)
Pending draft oncology, Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731, S 968, HR 1567), Follow-on Biologics (S 623 & HR 1956)
Medicare Improvements for Patients and Providers Act of 2008
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Medicare Improvements for Patients and Providers Act of 2008
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicare (HR 6331), Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038)
Medicare Improvements for Patients and Providers Act of 2008
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Issues related to intellectual property protection and market acccess within current trade negotiations; Turkey IPR and Pricing; Canada IP; USMCA Passage; Saudi Arabia; Thailand OCPA; Malaysia Compulsory Licenses; Special 301; Trade talks - US-Japan, US-China, US-EU, and US-UK
Intellectual property; 340B Program; PPACA; Medicare & Meidcaid prescription drug reimbursement and value; Senate Finance bill; Prescription Drug Pricing Reduction Act
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2019 · second_quarter · 2A
Implementation of the Tax Cuts and Jobs Act
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (NHHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
Issues related to intellectual property protection and market acccess within current trade negotiations; Turkey IPR and Pricing; Canada IP; USMCA Passage; Saudi Arabia; Thailand OCPA; Malaysia Compulsory Licenses; Special 301; Trade talks - US-Japan, US-China, US-EU, and US-UK
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA; Lower Health Care Costs Act (S 1895)
Intellectual property; Dormant Therapies Act; 340B Program; PPACA; Medicare & Meidcaid prescription drug reimbursement and value
Hatch Waxman Integrity Act
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2019 · second_quarter · Q2
Implementation of the Tax Cuts and Jobs Act
Intellectual property; Dormant Therapies Act; 340B Program; PPACA
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (NHHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
Issues related to intellectual property protection and market acccess within current trade negotiations; Turkey IPR and Pricing; Canada IP; USMCA Passage; Saudi Arabia; Thailand OCPA; Malaysia Compulsory Licenses; Special 301; Trade talks - US-Japan, US-China, US-EU, and US-UK
Hatch Waxman Integrity Act
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2019 · first_quarter · Q1
Intellectual property; Dormant Therapies Act; 340B Program; PPACA
Hatch Waxman Integrity Act
Implementation of the Tax Cuts and Jobs Act
Hospital discounts; 340B program
Sanitary and phytosanitary issues (SPS); Japan; Turkey (country) Pricing; IPR and Pricing; Canada IP; USMCA Passage; Saudi Arabia; Thailand OCPA; Malaysia Compulsory Licenses; Special 301
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (NHHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2018 · first_quarter · 1A
Tax reform
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA
Intellectual property; Dormant Therapies Act; 340B Program; Medicare Part B and Part D; PPACA; IPAB repeal
Hospital discounts; 340B program
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2018 · fourth_quarter · Q4
Sanitary and phytosanitary issues (SPS); Japan; Turkey (country) Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession; Saudi Arabia
Hospital discounts; 340B program
Implementation of the Tax Cuts and Jobs Act
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2018 · third_quarter · 3A
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (UNHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
Sanitary and phytosanitary issues (SPS); Japan; Turkey (country) Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2018 · third_quarter · Q3
Intellectual property
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (UNHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
Sanitary and phytosanitary issues (SPS); Japan; Turkey (country) Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2018 · second_quarter · Q2
Implementation of the Tax Cuts and Jobs Act
Intellectual property; Dormant Therapies Act; 340B Program; Bipartisian Budget of 2018; PPACA
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2018 · first_quarter · Q1
Intellectual property; Dormant Therapies Act; 340B Program; Medicare Part B and Part D; PPACA; IPAB repeal
Hospital discounts; 340B program
Tax reform
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2017 · fourth_quarter · 4A
Intellectual property; Dormant Therapies Act; 340B Program; Medicare Part B and Part D; PPACA; IPAB repeal
Tax reform
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2017 · fourth_quarter · 4A
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA; RACE Act
Tax reform
Intellectual property; Dormant Therapies Act; 340B Program; Medicare Part B and Part D; PPACA; IPAB repeal
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2017 · fourth_quarter · Q4
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA; RACE Act
Tax reform
Intellectual property; Dormant Therapies Act; 340B Program; Medicare Part B and Part D; PPACA; IPAB repeal
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2017 · third_quarter · 3A
Intellectual property; MODDERN Cures; Dormant Therapies Act; 340B Program; Medicare Part B and Part D; PPACA; IPAB repeal
Intellectual property; MODDERN cures
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA; RACE Act
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2017 · third_quarter · Q3
Sanitary and phytosanitary issues (SPS); Japan; Turkey Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA; RACE Act
Intellectual property; MODDERN Cures; Dormant Therapies Act; 340B Program; Medicare Part B and Part D; PPACA; IPAB repeal
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2017 · second_quarter · Q2
Intellectual property; MODDERN Cures; Dormant Therapies Act; 340B Program; Medicare Part B and Part D; PPACA; IPAB repeal
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA; RACE Act
Intellectual property; MODDERN cures
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2017 · first_quarter · Q1
Intellectual property; MODDERN Cures; Dormant Therapies Act; 340B Program; Medicare Part B and Part D; PPACA; IPAB repeal
Intellectual property; MODDERN cures
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2016 · second_quarter · 2A
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership; Trans-Pacific Partnership
Intellectual property; MODDERN Cures
Intellectual Property; MODDERN Cures; Dormant Therapies; 21st Century Cures; 340B Program; Part B
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2016 · fourth_quarter · Q4
Intellectual Property; MODDERN Cures; Dormant Therapies; 21st Century Cures; 340B Program; Part B; Medicare Part D, PPACA
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership; Trans-Pacific Partnership
Intellectual property; MODDERN Cures
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2016 · second_quarter · 2A
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership; Trans-Pacific Partnership
Intellectual Property; MODDERN Cures; Dormant Therapies; 21st Century Cures; 340B Program; Part B
Intellectual property; MODDERN Cures
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2016 · third_quarter · Q3
Intellectual property; MODDERN Cures
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership; Trans-Pacific Partnership
Intellectual Property; MODDERN Cures; Dormant Therapies; 21st Century Cures; 340B Program; Part B
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2016 · second_quarter · Q2
Intellectual Property; MODDERN Cures; Dormant Therapies; 21st Century Cures; 340B Program; Part B
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership; Trans-Pacific Partnership
Intellectual property; MODDERN Cures
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2016 · first_quarter · Q1
Intellectual property; MODDERN Cures
Intellectual Property; MODDERN Cures; Dormant Therapies; 21st Century Cures; 340B Program; Part B
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2015 · fourth_quarter · Q4
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership, TPP
Intellectual property; MODDERN Cures
Intellectual Property; MODDERN Cures; Dormant Therapies; 21st Century Cures; 340B Program; Part B
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2015 · third_quarter · Q3
Intellectual Property; MODDERN Cures; Dormant Therapies; 21st Century Cures; 340B Program; Part B
Intellectual property; MODDERN Cures
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership, TPP
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2015 · second_quarter · Q2
Intellectual Property; MODDERN Cures; Dormant Therapies; 21st Century Cures; 340B Program; Part B
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2015 · first_quarter · Q1
Deficit reduction issues; Part D; Rebates
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; Germany pricing reforms; Poland market access; CODEX; Portugal cost containment; Canada IP; Transatlantic Trade & Investment Partnership
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2014 · fourth_quarter · 4A
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Turkey Pricing; Russia pricing; IPR and Pricing; Germany pricing reforms; Poland market access; CODEX; Portugal cost containment; Canada IP; Transatlantic Trade & Investment Partnership; Asia Pacific Economic Cooperation; China IPR
Deficit reduction issues; Part D; Rebates
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2014 · fourth_quarter · Q4
Deficit reduction issues; Part D; Rebates
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Turkey Pricing; Russia pricing; IPR and Pricing; Germany pricing reforms; Poland market access; CODEX; Portugal cost containment; Canada IP; Transatlantic Trade & Investment Partnership; Asia Pacific Economic Cooperation; China IPR
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2014 · third_quarter · Q3
Deficit reduction issues; Part D; Rebates
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Turkey Pricing; IPR and Pricing; Germany pricing reforms; Poland market access; CODEX; Portugal cost containment; Canada IP; Transatlantic Trade & Investment Partnership; Colombia biologics
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2014 · second_quarter · Q2
Deficit reduction issues; Part D; Rebates
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Turkey Pricing; IPR and Pricing; Germany pricing reforms; Poland market access; CODEX; Portugal cost containment; Canada IP; Transatlantic Trade & Investment Partnership;
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2014 · first_quarter · Q1
Deficit reduction issues; Part D; Rebates
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Turkey Pricing; IPR and Pricing; Germany pricing reforms; Poland market access; CODEX; Portugal cost containment; Canada IP; Transatlantic Trade & Investment Partnership;
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2013 · fourth_quarter · Q4
Deficit reduction issues; Part D; Rebates
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Turkey Pricing; IPR and Pricing; Germany pricing reforms; Poland market access; CODEX; Portugal cost containment; Canada IP; Transatlantic Trade & Investment Partnership;
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2013 · third_quarter · Q3
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Russia PNTR; Turkey Pricing; IPR and Pricing; Germany pricing reforms; Poland market access; Spain IP/Pricing; Patent protection; CODEX; Portugal cost containment; Hungary cost containment; Canada IP; Poland market access; Greece price reform; Romania cost containment
Deficit reduction issues; Part D; Rebates
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2013 · second_quarter · Q2
Deficit reduction issues; Part D; Rebates
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Russia PNTR; Turkey Pricing; IPR and Pricing; Germany pricing reforms; Poland market access; Spain IP/Pricing; Patent protection; CODEX; Portugal cost containment; Hungary cost containment; Canada IP; Poland market access; Greece price reform; Romania cost containment
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2013 · second_quarter · Q2
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Russia PNTR; Turkey pricing; IPR and Pricing; Germany pricing reforms; Poland market access; Spain IP/Pricing; Patent Protection; CODEX; Portugal cost-containment; Hungary cost-containment; Canada IP; Poland market access; Greece price reform; Romania cost-containment
Deficit reduction issues; part D; rebates
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2013 · second_quarter · Q2
Sanitary and Phytosanitary issues (SPS); TPP; Japan; KORUS; Russia PNTR; Turkey pricing; IPR and Pricing; Germany pricing reforms; Poland market access; Spain IP/Pricing; Patent Protection; CODEX; Portugal cost-containment; Hungary cost-containment; Canada IP; Poland market access; Greece price reform; Romania cost-containment
Deficit reduction issues; Part D; Rebates
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2013 · first_quarter · Q1
Deficit reduction issues; Part D; Rebates
Sanitary and Phytosanitary issues (SPS); TPP; Japan; KORUS; Russia PNTR; Turkey pricing; IPR and Pricing; Germany pricing reforms; Poland market access; Spain IP/Pricing; Patent Protection; CODEX; Portugal cost-containment; Hungary cost-containment; Canada IP; Poland market access; Greece price reform; Romania cost-containment
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2012 · fourth_quarter · Q4
Deficit reduction issues; Part D; Rebates
Sanitary and Phytosanitary issues (SPS); TPP; Japan; KORUS; Russia PNTR; Turkey pricing; IPR and Pricing; Germany pricing reforms; Poland market access; Spain IP/Pricing; Patent Protection; CODEX; Portugal cost-containment; Hungary cost-containment; Canada IP; Poland market access; Greece price reform; Romania cost-containment
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2012 · third_quarter · Q3
PDUFA reauthorization; Patent protection; Drug shortages; 340B issues; PPACA
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2012 · second_quarter · Q2
PDUFA reauthorization; Patent protection
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2012 · first_quarter · Q1
PDUFA reauthorization, Patent Protection
SPS Issues; Veterinary Medicine; TPP; Russia PNTR; Turkey Pricing; IPR and Pricing; Germany Pricing Reforms; Poland Market Access; Greece Pricing Reform; Spain IP/Pricing
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2011 · fourth_quarter · Q4
TPP; Russia PNTR; Turkey Pricing; Veterinary Medicine - S/PS Issues; IPR and Pricing; Germany pricing reforms; Poland Market Access; Greece Pricing Reform; Spain IP/Pricing
Debt Commission; Patent Protection
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2011 · third_quarter · Q3
Medicare Part D non-interference and rebate issues
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2011 · second_quarter · Q2
Trans-Pacific Partnership Agreement; Korean Free trade Agreement; TPP IP/Market Access; ASEAN Countries Market Access/IP; IMF Policy on Greece; Veterinary medicine - domestic and international trade; Germany pricing reforms; Poland market access; Greece pricing reform; Romania cost-containment; CEE cost-containment; Anti-Counterfeiting; Turkey policy; PNTR for Russia
Medicare Part-D non-interference and rebate issues; Medicare Decisions Accountability Act of 2011 (IPAB repeal) (HR 452);
PFUFA V; Patient Protection and Affordable Care Act;
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2011 · first_quarter · Q1
340 B Legislation, PDUFA V, Importation, Patient Protection and Affordable Care Act
Medicare Part D Non-Interference, Rebate Issues, Medicare Decisions Accountability Act of 2011 - IPAB Repeal (HR 452)
Corporate Tax Reform, Patent Reform (S 23, HR 1249)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2010 · third_quarter · Q3
IPAB (S 3590, HR 4872); 340B legislation (S 3590, HR 4872); FDA Foreign Inspections (HR 759); PCORI (S 3590, HR 759); Implementation issues
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2010 · second_quarter · Q2
Healthcare Reform (HR 4872 & HR 3590); FOB provisions (HR 3200)
Healthcare Reform (HR 4872 & HR 3590)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2010 · first_quarter · Q1
Medicare reimbursement and coverage policies; Healthcare reform (HR 3590 & HR 4872); food safety; Patient Protection and Affordable Care Act (HR 3590); FOB provisions (HR 3200)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2009 · fourth_quarter · Q4
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2009 · second_quarter · Q2
Health Care Reform, Comparative Effectiveness Research (S 1213, HR 2502, S 1259), Drug Importation, Follow-on biologics (HR 1548, HR 1427, S 726)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2009 · first_quarter · Q1
Medicaid Rebate Increase, Medicaid rebate applied to Medicaid Managed Care Plans, Medicaid rebate applied to Part D, 340B Expansion (HR 444), Transparency
21st Century Cancer Access to Life-Saving Early Detection, Research and Treatment (S 717), Fair Medicaid Drug Payment and Genetic Information Nondiscription Act
Transparency
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · second_quarter · 2A
Sunshine Act (S 2029, HR 5605)
Medicare (HR 6331), Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038)
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · second_quarter · Q2
Pending draft oncology, Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Medicare (HR 6331), Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038)
Sunshine Act (S 2029, HR 5605)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · first_quarter · 1A
Transparency (HR 1669)
Access for uninsured (S 1886 & S 1975), Biosimilars (S 1695 & HR 5629), healthcare reform, United Kingdom (pricing reform), Italy (healthcare reform & pricing), Germany (healthcare reform & pricing), France (healthcare reform & pricing), funding to fight tuberculosis (HR 5501, S 2731, S 968, HR 1567), Follow-on biologics (S 623 & HR 1956)
Fair Medicaid Drug Payment Act (S 1951), Genetic Information Nondiscription Act (HR 493)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · fourth_quarter · Q4
Medicare, Medicaid
Comparative Effectiveness (S 3408); Food & Drug Safety (HR 3610); Biosimilars (HR 5629, HR 1956, HR 1038, S 1695); Transparency (S 2029, HR 5605); Healthcare Reform (Belgium, Germany, Italy, United Kingdom, South Africa); MDR-TB
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · third_quarter · Q3
Healthcare Reform in Belgium, Germany, Italy, United Kingdom, South Africa, and MDR-TB, Comparative Effectiveness (S 3408), Food & Drug Safety (HR 3610), Biosimilars (HR 5629), Transparency (S 2029 & HR 5605)
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · second_quarter · Q2
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Sunshine Act (S 2029, HR 5605)
Medicare (HR 6331), Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · first_quarter · Q1
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731, S 968, HR 1567), Follow-on Biologics (S 623 & HR 1956)
Fair Medicaid Drug Payment Act (S 1951), Genetic Information Nondiscription Act (HR 493)
Transparency (HR 1669)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2007 · year_end · YY
Importation (S 1644, HR 2368, HR 2900, HR 3161) Anti-counterfeiting Free Trade Agreements
PDUFA (S 1082 & HR 2900) Prescription Drug User Fee Act Counterfeiting (S 242, HR 380)
SCHIP (HR 3162) Medicare (S 250 & HR 4) Average Manufacturer Proce (S 1951)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2007 · mid_year · MM
Importation (S 1644 & HR 2638 & HR 2900), Anti-counterfeiting, Free Trade Agreement
Intellectual Property, Patent Reform (S 3818 & HR 1908), Follow-on Biologics (S 1695), Compulsory Licensing, Counterfeiting
Medicare (S 250 & HR 4), SCHIP
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2006 · year_end · YY
Health Care Reform Pricing Issues Importation
Intellectual Property Patent Reform (S3818)
International Trade Issues -- Peru FTA, Poland Price Cut, Germany Jumbo Groups, Japan Pricing & Regulatory Reform, Korea FTA, Russia WTO
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2006 · mid_year · MM
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2005 · year_end · YY
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2005 · mid_year · MM
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2004 · mid_year · MM
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2003 · mid_year · MM
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Intellectual property; Dormant Therapies Act; 340B Program; Bipartisian Budget of 2018; PPACA
Hatch Waxman Integrity Act
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (UNHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Implementation of the Tax Cuts and Jobs Act
Hatch Waxman Integrity Act
Intellectual property; Dormant Therapies Act; 340B Program; Bipartisian Budget of 2018; PPACA
Hospital discounts; 340B program
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA
Implementation of the Tax Cuts and Jobs Act
Hospital discounts; 340B program
Intellectual property; Dormant Therapies Act; 340B Program; Bipartisian Budget of 2018; PPACA
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Hospital discounts; 340B program
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Sanitary and phytosanitary issues (SPS); Japan; Turkey Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Intellectual property; MODDERN cures
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Sanitary and phytosanitary issues (SPS); Japan; Turkey Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
America Invents Act (patent reform)(HR 1249); Anti-Counterfeiting; Patient safety
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Security Agency (NSA), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Pending draft oncology, Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Sunshine Act (S 2029, HR 5605)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Security Agency (NSA), Natl Security Council (NSC), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Pending draft oncology, Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Sunshine Act (S 2029 / HR 5605)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Security Agency (NSA), Natl Security Council (NSC), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Patent Reform (S 1145 & HR 1908) Intellectual Property Rights Enforcement (S 522) Compulsory Licensing (Thailand) Product Patent Issues (Norway & Spain) Regulatory & IP Reform (Japan, Korea, China, Taiwan, India, Thailand, Philippines, Russia, Turkey, Poland, Czech Republic, Mexico)
Follow-on Biologics (HR 1956)
Direct to Consumer Advertising
Health Care Reform Uninsured (S 1019) Stop Tuberculosis Now (S 968 & HR 1567) MDR-TB
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Follow-on Biologics (S 1695)
Prescription Drug User Fee Act (S 1082 & HR 2900)
Uninsured (S 1019), D-ATLAS, Tri-Care (S 1547 & HR 1585), MDR-TB (S 968 & HR 1567), Health Care Reform
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Health Technology
Medicare implementation Non-interference MMA & Patient Assistance Programs Mental Health Access
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)